Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02845336 · ClinicalTrials.gov registry record · Phase 2
Celecoxib for Thyroid Eye Disease
A Phase 2 study, sponsored by Johns Hopkins University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT02845336: Clinical Trial Phase 2 study, sponsored by Johns Hopkins University.
NCT02845336 is a Phase 2 study that was terminated before completion, run by Johns Hopkins University. The registered enrollment target is 7 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02845336, a Phase 2 study, was terminated before completion, sponsored by Johns Hopkins University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
Thyroid eye disease (TED) is an autoimmune disorder in which the immune system attacks orbital tissues, resulting in characteristic changes in eyelid position, globe position in the orbit, extraocular muscle balance, and optic nerve function. TED is a potentially blinding disease, and current treatments largely consist of nonspecific reduction of inflammation using corticosteroids or radiation therapy. Regardless of treatment, once TED progresses from its inflammatory phase to a more fibrotic, resolution phase, the orbital changes become fixed and can be modified only by surgery. The investigators propose to treat a cohort of patients with active TED using a selective COX-2 inhibitor, celecoxib, and to compare these patients to an observational control group. The investigators hypothesize that celecoxib will reduce the severity of disease and/or prevent progression to proptosis, diplopia, and corneal exposure or compressive optic neuropathy.
Interventions
- DRUG Celecoxib
- DRUG artificial tears
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2017-03-05 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02845336
The ClinicalTrials.gov registry entry for NCT02845336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Johns Hopkins University, which has 1,448 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Celecoxib is the first listed.
NCT02845336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02845336 about?
NCT02845336 is a clinical study titled "Celecoxib for Thyroid Eye Disease". Thyroid eye disease (TED) is an autoimmune disorder in which the immune system attacks orbital tissues, resulting in characteristic changes in eyelid position, globe position in the orbit, extraocular muscle balance, and optic nerve function. TED is a potentially blinding disease, and current treatm...
What is the current status of trial NCT02845336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2017-03-05. Estimated completion is 2019-06-30.
What interventions are being tested in trial NCT02845336?
The interventions under investigation include: Celecoxib (DRUG), artificial tears (DRUG).
Who is sponsoring clinical trial NCT02845336?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.